Physiological and Functional Effects of Percutaneous Neuromodulation vs Transcutaneous Neuromodulation

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

February 16, 2024

Study Completion Date

April 30, 2024

Conditions
Stroke/Brain Attack
Interventions
DEVICE

Percutaneous neuromodulation

Patients will receive a needle circuit approaching the deep peroneal nerve in an echoguided manner. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.

DEVICE

Transcutaneous neuromodulation

Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.

DEVICE

Placebo-percutaneous

Patients will have the neuromodulation circuit placed with needles at 0 intensity, approaching the deep peroneal nerve in an ultrasound-guided manner.

DEVICE

Placebo-transcutaneous

patients will have the electrodes placed over the tibialis anterior muscle at intensity 0.

DEVICE

Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)

Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.

Trial Locations (1)

Unknown

Mª Dolores Apolo Arenas, Badajoz

All Listed Sponsors
lead

University of Extremadura

OTHER